ClinicalTrials.gg
CompletedNCT02244242Updated Sep 19, 2014

Study to Evaluate the Symptomatic Relief Effects of FLOMAX® in Patients With Signs and Symptoms of Benign Prostatic Hyperplasia

A Phase 4 interventional study of Tamsulosin hydrochloride in Prostatic Hyperplasia, sponsored by Boehringer Ingelheim. Completed. Open to male participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2014-09-19.

Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
493
Allocation
Non-randomized
Ages
45 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 48 studies testing tamsulosin in Prostatic Hyperplasia — 8 open to participants now, 8 under way, 1 of them phase 3. Tamsulosin · Prostatic Hyperplasia.

Enrollment
11th of 48
493 · median 118
Started
1998
with 2 others
Phase 4
17 of 48
4 open now
Registered
19th of 48
by date
Lead sponsor
5 of 48
Boehringer Ingelheim

Among the 48 studies testing tamsulosin in Prostatic Hyperplasia, this one is the 11th largest by enrollment, is one of 3 that started in 1998, is one of 17 in phase 4, and was the 19th registered.

Prostatic Hyperplasia

828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

8 of the 48 studies testing tamsulosin in Prostatic Hyperplasia are open now, in 3 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About tamsulosin

Tamsulosin: first FDA approval 1997 (FLOMAX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 45 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies testing tamsulosin in Prostatic Hyperplasia, or all of them as a file.
02

Study summary

Study to evaluate the symptomatic relief afforded by tamsulosin hydrochloride capsules in patients with signs and symptoms of benign prostatic hyperplasia (BPH). Additionally to provide primary care physicians experience with the use of tamsulosin hydrochloride capsules 0.4 mg daily for the treatment of BPH

03

Conditions studied

  • Prostatic Hyperplasia

Browse trials for

04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male patients (45 years of age or older) diagnosed with BPH who scores at least 13 points on the AUA Symptom Score Index at baseline
  • Patients who have a baseline Prostate specific antigen (PSA) of >= 4.0 ng/ml
  • Patients who provide written prior to participation in the study in accordance with regulatory requirements
  • Patients who have been judged by the investigator to be reliable and who have agreed to cooperate with all tests and examinations stipulated in the protocol

Exclusion criteria

Exclusion Criteria:

  • Patients who have previously been diagnosed with prostate cancer
  • Patients who have an abnormal Digital rectal examination (DRE) of the prostate gland at baseline other than enlargement (i.e., patients with suspicious areas or nodularity of the gland which may indicate possible prostatic carcinoma are to be excluded)
  • Patients who have had previous invasive or non-invasive surgical treatment of the prostate gland
  • Patients who have had an episode of acute urinary retention within four weeks of the screening visit
  • Patients who have a history or evidence of urethral stricture
  • Patients who have had pelvic radiotherapy
  • Patients who have a history of chronic prostatitis
  • Patients who have a history of neurogenic bladder
  • Patients who have had a urinary tract infection (i.e. positive urine culture yielding pathogenic bacteria >= 10**5 colony forming units per ml or a laboratory report of a urinary tract infection) or symptoms/signs indicative of a urinary tract infection such as: increased white blood cells (WBCs) in the urine (15-30 WBC/high powered field [hpf], dysuria, costovertebral tenderness and urinary frequency accompanied by fever within four weeks of baseline
  • Patients who have evidence of significant renal dysfunction based upon a serum creatinine greater than two times the levels established by the central laboratory used in this study
  • Patients who have baseline clinical laboratory test results that indicate the following values:

    • : \< 12.0 g/dl
    • Leukocytes: \< 3000 mm³
    • Liver enzymes: Serum Glutamic Oxaloacetic Transaminase (), Serum Glutamic Pyruvic Transaminase (SGPT), Gamma-Glutamyl Transferase (GGT) and alkaline phosphatase): More than two times the upper limit of normal levels established by the central laboratory used in the study
  • Patients who have postural symptoms (e.g. lightheadedness, dizziness and fainting occurring with or without a change in Blood Pressure (BP) and/or Heart Rate (HR) within four weeks of baseline
  • Patients who have participated in another drug study within four weeks of baseline
  • Patients who have conditions which might interfere with the patient's ability to participate in the study including (but not limited to) the following:

    • neurologic, gastrointestinal, cardiovascular (including uncontrolled hypertension defined as a sitting diastolic BP >= 95 mmHg with or without treatment), hepatic, renal, psychiatric, hematologic or respiratory disease or clinically relevant laboratory abnormalities based upon the investigator's judgment
  • Patients who have had cancer or a diagnosis of cancer within five years of baseline
  • Patients who have received cimetidine, warfarin or herbal medication specifically for treatment of any urological problems within four weeks prior or baseline
  • Patients who have known allergy to study medication
  • Patients who are currently receiving finasteride or who have been treated with finasteride within three months prior to baseline
  • Patients who have documented myocardial infarction (by ) within the past 6 months or evidence of a myocardial infarction on an ECG where the date could not be determined
  • Patients who are classified as (NYHA) Class III or IV congestive heart failure
  • Patients who have prosthetic heart valves, cardiac devices or history of endocarditis
  • Patient who have clinically significant cardiac arrhythmias as diagnosed by ECG whether or not accompanied by symptoms (e.g., dizziness, presyncope, syncope, unsteadiness)
  • Patients who have received the following drugs within two weeks prior to baseline and who are unable to discontinue these drugs for the remainder of the study:

    1. Alpha-adrenergic blocking agents
    2. Alpha-adrenergic agonists
    3. Drugs with anticholinergic activity including antihistamines
    4. Antispasmodics
    5. Parasympathomimetics and cholinomimetics
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
493 participants (actual)

Study arms

  • Experimental
    Tamsulosin hydrochloride

    modified release capsules

    Drug: Tamsulosin hydrochloride

Interventions

06

What researchers measure

Primary outcomes

  1. Change in American Urological Association (AUA) Symptom Score Index by means of a patient self-assessment questionnaire

    Time frame: up to 45 days

Secondary outcomes

  1. Change of AUA Bother Score Index by means of a patient self-assessment questionnaire

    Time frame: up to 45 days

  2. Change in BPH Impact Index by means of a patient self-assessment questionnaire

    Time frame: up to 45 days

  3. Global Assessment of investigator on 5-point scale

    Time frame: at 4, 8 and 45 days

  4. Number of patients with adverse events

    Time frame: up to 59 days

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 1998 and a primary completion of Aug 1999. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2014
First posted
Sep 19, 2014
Start
Jul 1998
Primary completionActual
Aug 1999
Last update
Sep 19, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02244242
Responsible party
Sponsor
First posted
Sep 19, 2014
Start date
Jul 1998
Primary completion
Aug 1999
Last update
Sep 19, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tamsulosin

Start the discussion